Human Papillomavirus and Genital Cancer

Dear Colleagues,

Currently, cervical cancer is the fourth most common cause of tumors affecting the female population worldwide. The main causative factor is cervical infection sustained by human papillomavirus (HPV). 15.4% of all human cancers are caused by viral infectious agents; of these, 30% of cases are due to HPV infection. Neoplastic evolution is a rare event that occurs in only 0.3-1.2% of HPV infections; such infections are frequent in the population, representing the second cause for the incidence of sexually transmitted infections (STIs), as well as the first in industrialized countries. The lifetime risk of contracting an HPV infection is estimated to be 80%. 

However, the relative rarity of tumor evolution compared to the infectious state suggests that other conditions for neoplastic evolution are involved between host, virus and environment. Improved knowledge of the role of single or multiple HPV infections sustained by high-risk genotypes will be essential to organize future screening and to evaluate the susceptibility to progression of high-risk cervical lesions. In addition, the role of an anti-HPV preventive vaccine represents a significant instrument for primary prevention of HPV-related disease. Several studies have evaluated potential applications of the HPV vaccine as well as the vaccine’s impact on disease pathogenesis.

We are welcome you to  contribute related papers to us, to discuss the latest research and new ideas in the field.

Dr. Mattia Dominoni 

Guest Editor

Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 1500 USD. Submitted manuscripts should be well formatted in good English.